Humacyte, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Humacyte, Inc. (HUMA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $1.02 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-12
- Humacyte, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $1.06, a 76.70% decline year-over-year.
- Humacyte, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $4.55, a 35.01% increase year-over-year.
- Humacyte, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $3.37, a 18.25% increase year-over-year.
- Humacyte, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $2.85, a 51.69% decline year-over-year.
- Humacyte, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $3.30, a 46.60% decline from fiscal 2024.
- Humacyte, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $6.18, a 116.08% increase from fiscal 2023.
- Humacyte, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $2.86, a 19.21% decline from fiscal 2022.
- Humacyte, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $3.54, a 65.46% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.02 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | $1.06 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $3.30 10-K · filed 2026-03-27 | |||
| 2025-09-30 | $4.07 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $4.08 10-Q · filed 2025-08-11 | |||
| 2025-03-31 | $4.55 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $6.18 10-K · filed 2025-03-31 | |||
| 2024-09-30 | $6.36 10-Q · filed 2024-11-08 | |||
| 2024-06-30 | $6.61 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | $3.37 10-Q · filed 2024-05-13 | |||
| 2023-12-31 | $2.86 10-K · filed 2024-03-28 | |||
| 2023-09-30 | $3.52 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $3.47 10-Q · filed 2023-08-14 | |||
| 2023-03-31 | $2.85 10-Q · filed 2023-05-12 | |||
| 2022-12-31 | $3.54 10-K · filed 2023-03-24 | |||
| 2022-09-30 | $5.00 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $5.56 10-Q · filed 2022-08-12 | |||
| 2022-03-31 | $5.90 10-Q · filed 2022-05-13 | |||
| 2021-12-31 | $10.25 10-K · filed 2022-03-29 | |||
| 2021-09-30 | $10.28 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |